GDTC · CytoMed Therapeutics Ltd
Market Cap
$10.75M
Shares
11.83M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.91
Open$0.92
Day$0.76–0.92
52W close$0.72–2.69
Avg vol 30d150K
Short int4K · 0.0% float · 1.0d
Short vol98%
DataApr 2023–Aug 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−20%
below
Price vs 50-day avg
−4%
below
RSI (14)
48
neutral
MACD trend
Positive
52-week position
9%
near low
Momentum
relative strength
1-month return
−1%
trailing
6-month return
−14%
trailing
YTD return
−32%
this year
Relative strength
−28%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Accumulating
Net +$300.0K over 90 days · 0% sells
Short interest
Falling
0.04% of float · ▼ -25.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Squeeze score
29
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−73%
past year
ATR
10.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−20%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
48
Neutral
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Flat
0% holders QoQ · +1 funds added
Insider flow
Accumulating
Net +$300.0K over 90 days · 0% sells
Short interest
Falling
0.04% of float · ▼ -25.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
3 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 9%
Range high $3
vs 200-day avg -20%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GDTC
this stock
CytoMed Therapeutics Ltd
|
$10.75M | -31.9% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.8% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +6.7% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.51B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
3
- % held
- 0.1%
- Net QoQ
- -4.5K sh
- Top holder
- Axiom Investment Manageme…
Held
Float
Short & Settlement
Smart Money
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GDTC | -9.1% | -1.1% | -14.3% | -2.3% | -31.9% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -9.6% | -2.4% | -27.5% | -5.0% | -44.4% |